Novartis announced the company has ranked first place in the 2026 Access to Medicine Index. Published every two years, the Index is an independent assessment of how major research-based pharmaceutical companies are improving access to medicines.
“Being ranked first in the Access to Medicine Index for the second consecutive time is an honor, and a recognition of our continued efforts to expand access to healthcare together with our partners,” said Vas Narasimhan, CEO of Novartis. “We remain committed to transforming scientific progress into meaningful impact for more patients around the world.”
The ranking retains Novartis’ leading position in the Index since 2024, with the company scoring an overall 3.86 out of five in 2026. Novartis also ranked first across all individual Technical Areas assessed, the only company to do so since the Index was first published in 2008, including a score for R&D almost twice the sector average.
The Index is published by the Access to Medicine Foundation, an independent non-profit organization, which assesses 20 of the world’s largest research-based pharmaceutical companies on their efforts to improve access to medicines, vaccines and diagnostics across 84 diseases across 113 low- and middle-income countries.¹
Companies were assessed on three Technical Areas in 2026: Governance of Access, which scores how companies embed accountability for access; Research & Development, which evaluates R&D activity and access planning for diseases affecting low- and middle-income countries; and Product Delivery, which tracks how companies reach patients and address barriers to access.
